Guillain

Guy Burrows, M.D., Board-Certified Neurologist and Peripheral Nerve Specialist, Unveils Clinical Center Dedicated to Neuromuscular and Autoimmune Disorders

Retrieved on: 
Tuesday, January 4, 2022
FDA, Biotechnology, Diabetes, Alternative Medicine, AIDS, Health, Surgery, Teens, Parenting, Children, LGBTQ+, Baby, Maternity, Insurance, Professional Services, Other Science, Stem Cells, Research, Practice Management, Physical Therapy, Managed Care, Software, General Health, Women, Seniors, Men, Technology, Family, Other Health, Consumer, Radiology, Pharmaceutical, Oncology, Mental Health, Medical Devices, Infectious Diseases, Hospitals, Genetics, Science, Fitness & Nutrition, Veterinary, Nursing, Clinical Trials, Medical Supplies, Cardiology, Spasm, George Washington University School of Medicine & Health Sciences, Guillain, Outline of health sciences, Degenerative disease, CIDP, Burrows, MG, Health, Patient, Amyotrophic lateral sclerosis, Chronic inflammatory demyelinating polyneuropathy, Hypoesthesia, IVIG, LinkedIn, Torney General Hospital, Suite, Diagnosis, Pain, Pain scale, ALS, Injection, Myasthenia gravis, Cedars-Sinai Medical Center, Peripheral neuropathy, Multimedia, Neuromuscular Disorders, Logging, Medical device, Medicine, Facebook

, a leading Houston-based, board-certified neurologist, announced the opening of a clinical center solely dedicated to treating those with peripheral nerve conditions and neuromuscular disorders.

Key Points: 
  • , a leading Houston-based, board-certified neurologist, announced the opening of a clinical center solely dedicated to treating those with peripheral nerve conditions and neuromuscular disorders.
  • His peers and patients widely recognize Dr. Burrows for his fellowship training in peripheral nerve disorders and neuromuscular diseases, combined with his three decades of experience diagnosing and treating patients with complex muscle and nerve conditions.
  • Dr. Burrows received his medical degree at George Washington University School of Medicine and Health Sciences in Washington, D.C.
    Burrows Muscle and Nerve Center was founded as a dedicated clinical center focused on treating peripheral nerve and neuromuscular disorders and autoimmune conditions.
  • Headed by a board-certified neurologist and peripheral nerve specialist Guy Burrows, M.D., Burrows Muscle and Nerve Center treats a broad range of muscle and nerve conditions.

Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Tuesday, November 9, 2021
Appointment, Guillain, Clinical trial, Terminology, Food, Securities Exchange Act of 1934, CSO, D, COVID-19, Treatment, Serum, Amyotrophic lateral sclerosis, Association, Complement component 1q, Drug Quality and Security Act, Neurodegeneration, Safety, HD, GBS, AFL, SAN, Technology, Probability, Securities Act of 1933, Forward-looking statement, Research, GLOBE, Internal, Patient, FDA, Brain, Data, Coronavirus Scientific Advisory Board (Turkey), Private Securities Litigation Reform Act, G&A, Orphan drug, R, Eye, SEC, Drug discovery, Autoimmunity, CIO, Investment, ALS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, Natural history, Pharmaceutical industry, Risk management, Vaccine

The third quarter marks another quarter of meaningful progress with our portfolio, including effectively advancing three clinical-stage product candidates in five clinical trials, said Douglas Love, Esq., president and chief executive officer of Annexon.

Key Points: 
  • The third quarter marks another quarter of meaningful progress with our portfolio, including effectively advancing three clinical-stage product candidates in five clinical trials, said Douglas Love, Esq., president and chief executive officer of Annexon.
  • Second C1q Series R&D Event Highlights Neurodegeneration Franchise: Annexon hosted its secondC1q Series event, which spotlighted the companys neurodegeneration franchise and approach to treating complement-mediated neurodegenerative diseases.
  • Research and development (R&D) expenses: R&D expenses were $27.6 million for the quarter ended September 30, 2021, compared to $11.8 million for the quarter ended September 30, 2020.
  • General and administrative (G&A) expenses: G&A expenses were $8.1 million for the quarter ended September 30, 2021, compared to $3.8 million for the quarter ended September 30, 2020.

Guillain-Barre Syndrome Pipeline Review, H2 2020: 9 Companies, 10 Drug Profiles, Development Milestones, - ResearchAndMarkets.com

Retrieved on: 
Monday, December 14, 2020
General Health, Pharmaceutical, Health, Autoimmune diseases, Guillain, Barre, Organ systems, Branches of biology, Pipeline, Clinical medicine

The "Guillain-Barre Syndrome - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Guillain-Barre Syndrome - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Guillain-Barre Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Guillain-Barre Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Pipeline Review for Guillain-Barre Syndrome - H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 18, 2020
Health, Pharmaceutical, Autoimmune diseases, Guillain, Barre, Pipeline, Drug pipeline, Clinical medicine, Medical specialties, Health

The "Guillain-Barre Syndrome - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Guillain-Barre Syndrome - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This Pharmaceutical and Healthcare latest pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Guillain-Barre Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Janssen Presenting Data From Its Expanding Rheumatology Portfolio At The 2019 Annual Meeting Of The American College Of Rheumatology

Retrieved on: 
Thursday, October 31, 2019
Medical specialties, Drugs, Medicine, Monoclonal antibodies, Janssen Biotech, TNF inhibitors, Immunology, RTT, Golimumab, Infliximab, Guillain–Barré syndrome, Guillain

Rarely, people using TNF blockers, including SIMPONI ARIA, can have nervous system problems such as multiple sclerosis or Guillain-Barr syndrome.

Key Points: 
  • Rarely, people using TNF blockers, including SIMPONI ARIA, can have nervous system problems such as multiple sclerosis or Guillain-Barr syndrome.
  • If this occurs, your body may not make enough blood cells to help fight infections or help stop bleeding.
  • Please read the full Prescribing Information and Medication Guide for SIMPONI ARIAand discuss any questions you have with your doctor.
  • The Janssen Pharmaceutical Companies market REMICADEin Canada, Central and South America, the Middle East, Africa and Asia Pacific.

Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Guillain Barré Syndrome

Retrieved on: 
Monday, April 15, 2019
Autoimmune diseases, Medical specialties, RTT, Medicine, Guillain–Barré syndrome, Autoimmunity, Guillain, Health

The study will enroll up to 30 patients at approximately ten clinics in France, U.K. and the Netherlands over the next 18 months.

Key Points: 
  • The study will enroll up to 30 patients at approximately ten clinics in France, U.K. and the Netherlands over the next 18 months.
  • In 2018, the U.S. Food and Drug Administration granted Orphan Drug Designation to imlifidase for the treatment of GBS.
  • "Our novel IgG degrading enzyme, imlifidase, has potential in an array of acute autoimmune diseases, including Guillain Barr Syndrome.
  • Efficacy data reported from four Phase 2 studies have demonstrated that imlifidase rapidly and significantly reduced these DSAs, enabling transplantation.

Guillain-Barre Syndrome - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2019
Health, Pharmaceutical, Guillain–Barré syndrome, RTT, Pipeline, Barre, Guillain, Drug pipeline, Health, Medical specialties, Medicine

The "Guillain-Barre Syndrome - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Guillain-Barre Syndrome - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Guillain-Barre Syndrome development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report covers pipeline activity across the complete product development cycle i.e.

Guillain-Barr Syndrome Treatment to 2023 - The Global Market is Growing at a Flourishing Rate due to Strategic Alliances

Retrieved on: 
Monday, December 10, 2018
RTT, Autoimmune diseases, Guillain–Barré syndrome, Health, Guillain, Pharmaceutical industry, Medicine

The Guillain-Barr syndrome treatment market will register a CAGR of more than 5% by 2023.

Key Points: 
  • The Guillain-Barr syndrome treatment market will register a CAGR of more than 5% by 2023.
  • Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barr syndrome.
  • The recent approvals of novel immunoglobulins from regulatory bodies are expected to propel the growth of the global Guillain-Barr syndrome treatment market during the forecast period.
  • Factors such as the recent approvals of immunoglobulins and strategic alliances, will provide considerable growth opportunities to Guillain-Barr syndrome treatment manufactures.

The Guillain-barré Syndrome Treatment Market will register a CAGR of more than 5% by 2023

Retrieved on: 
Thursday, December 6, 2018
RTT, Autoimmune diseases, Guillain, Medicine, Veterinary medicine

Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barr syndrome.

Key Points: 
  • Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barr syndrome.
  • Technavio's analysts have predicted that the Guillain-Barr syndrome treatment market will register a CAGR of more than 5% by 2023.
  • The recent approvals of novel immunoglobulins from regulatory bodies are expected to propel the growth of the global Guillain-Barr syndrome treatment market during the forecast period.
  • For the detailed list of factors that will drive and challenge the growth of the Guillain-Barr syndrome treatment market during the 2019-2023, view our report.